In late antiquity, under Roman law, daughters inherited equally from their parents if no will was produced. In addition, Roman law recognized wives property as legally separate from husbandss property, as did some legal systems in parts of Europe and colonial Latin America. Christian cultures claim to be guided by the New Testament in regard to their view on the position of a wife in society as well as her marriage. The New Testament condemns divorce for both men and women (1 Cor 7:10–11), and assumes monogamy on the part of the husband: the wife is to have her "own" husband, and the husband is to have his "own" wife (1 Cor 7:2). In the medieval period, this was understood to mean that a wife should not share a husband with other wives. As a result, divorce was relatively uncommon in the pre-modern West, particularly in the medieval and early modern period, and husbands in the Roman, later medieval and early modern period did not publicly take more than one wife. In pre-modern times, it was unusual to marry for love alone, although it became an ideal in literature by the early modern period. In the 12th century, the Roman Catholic Church drastically changed legal standards for marital consent by allowing daughters over 12 and sons over 14 to marry without their parents approval, even if their marriage was made clandestinely. Parish studies have confirmed that late medieval women did sometimes marry against their parents approval.
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency for the same indication. Clinical trials have demonstrated its efficacy against certain Gram-positive bacteria including MRSA. Indications
Retapamulin is indicated for the topical treatment of impetigo due to Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes. Pharmacology
Mechanism of action
Retapamulin is an antibacterial agent, specifically a protein synthesis inhibitor. The medication selectively inhibits bacterial protein synthesis by interacting at a site on the 50S subunit of the bacterial ribosome through an interaction that differs from other antibiotics. Pharmacokinetics
Systemic exposure following topical application through intact skin is low. Contraindications
None yet reported. Adverse reactions
The most common reported adverse reaction was irritation at the application site. == References ==